SEC Form 4 · accession 0001985604-26-000003
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda Burkly
Officer — EVP, CHIEF SCIENTIFIC OFFICER
Period of report
Sep 3, 2026
Accepted (ET)
Sep 4, 2026 · 4:27 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 3, 2026 | S | 709 | $3.0372 | D | 61,660 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
- F2This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.